...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of clinical apheresis. >The treatment of acute liver failure with fractionated plasma separation and adsorption system: Experience in 85 applications.
【24h】

The treatment of acute liver failure with fractionated plasma separation and adsorption system: Experience in 85 applications.

机译：分步血浆分离和吸附系统治疗急性肝衰竭的经验：85年的应用经验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Artificial liver support systems represent a potential useful option for the treatment of liver failure. The outcomes of patients treated with the fractionated plasma separation and adsorption (FPSA) system are presented. PATIENTS AND METHODS: FPSA was performed 85 times for 27 patients (median 3 treatments/patient) with liver failure [85.2% acute liver failure (ALF) and 14.8% acute-on-chronic liver failure] using the Prometheus 4008H (Fresenius Medical Care) unit. Citrate was used for anticoagulation. A variety of clinical and biochemical parameters were assessed. Comparisons between pretreatment and post-treatment data were performed using paired t-test. RESULTS: The 85 sessions had a mean duration of 6 h. There were significant decreases in total bilirubin (13.18 +/- 9.46 mg/dL vs. 9.76 +/- 7.05 mg/dL; P < 0.0001), ammonia (167.6 +/- 75 mg/dL vs. 120 +/- 43.8 mg/dL; P < 0.0001), blood urea nitrogen (BUN; 12.55 +/- 13.03 mg/dL vs. 8.18 +/- 8.15 mg/dL; P < 0.0001), creatinine (0.54 +/- 0.47 mg/dL vs. 0.46 +/- 0.37 mg/dL; P = 0.0022) levels, and in pH (7.48 +/- 0.05 vs. 7.44 +/- 0.08; P = 0.0045). Four patients (14.8%) received liver transplantation after the treatments; in nine patients, transplantation was not necessary anymore (33%); the remaining 14 patients did not receive a transplantation because they were either not appropriate candidates or no organ was available. Overall survival was 48.1% (4 transplanted and 9 treated patients). No hematological complications related to FPSA were observed. CONCLUSIONS: FPSA system is a safe and effective detoxification method for patients with liver dysfunction, including ALF. The system is useful as a symptomatic treatment before liver transplantation; in up to 1/3 of the cases, it can even be used as a sole method of treatment.
机译：简介：人工肝支持系统代表了治疗肝衰竭的潜在有用选择。介绍了采用分级血浆分离和吸附（FPSA）系统治疗的患者的结局。患者和方法：使用Prometheus 4008H（Fresenius Medical Care）对27例肝衰竭[85.2％急性肝衰竭（ALF）和14.8％急性慢性肝衰竭]的肝衰竭患者进行了FPSA 85次。 ）单位。柠檬酸盐用于抗凝。评估了各种临床和生化参数。使用配对t检验对治疗前和治疗后数据进行比较。结果：85个疗程平均持续6小时。总胆红素（13.18 +/- 9.46 mg / dL与9.76 +/- 7.05 mg / dL; P <0.0001），氨（167.6 +/- 75 mg / dL与120 +/- 43.8 mg / dL; P <0.0001），血尿素氮（BUN; 12.55 +/- 13.03 mg / dL vs. 8.18 +/- 8.15 mg / dL; P <0.0001），肌酐（0.54 +/- 0.47 mg / dL vs. 0.46 +/- 0.37 mg / dL; P = 0.0022）水平和pH值（7.48 +/- 0.05对7.44 +/- 0.08; P = 0.0045）。治疗后有4例（14.8％）接受了肝移植。 9例患者不再需要移植（33％）;其余的14名患者由于不适合作为候选者或没有可用的器官而没有接受移植。总生存率为48.1％（4例移植患者和9例接受治疗的患者）。没有观察到与FPSA相关的血液学并发症。结论：FPSA系统是一种安全有效的排毒方法，用于包括ALF在内的肝功能不全患者。该系统可用作肝移植前的对症治疗;在多达1/3的情况下，它甚至可以用作唯一的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号